(Q53341834)

13 May 2018

title

Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: A Norwegian observational study. (English)

1 reference

13 May 2018

inflammatory bowel diseases

main subject

1 reference

1

Jørgen Jahnsen

1 reference

13 May 2018

author name string

Trond Espen Detlie

series ordinal

2

1 reference

13 May 2018

Simen Vatn

series ordinal

3

1 reference

13 May 2018

Petr Ricanek

series ordinal

4

1 reference

13 May 2018

publication date

1 January 2015

1 reference

13 May 2018

Expert Review of Gastroenterology & Hepatology

published in

1 reference

13 May 2018

volume

9 Suppl 1

1 reference

13 May 2018

page(s)

45-52

1 reference

13 May 2018

Maintenance of remission with infliximab in inflammatory bowel disease: efficacy and safety long-term follow-up

cites work

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1091308

Immunopathogenesis of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1091308

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1091308

Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1091308

Infliximab for the treatment of fistulas in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1091308

Infliximab for induction and maintenance therapy for ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1091308

Infliximab maintenance therapy for fistulizing Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1091308

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1091308

Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1091308

Tumor necrosis factor antagonist mechanisms of action: a comprehensive review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1091308

The economic burden of TNFα inhibitors and other biologic treatments in Norway

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1091308

Review article: Infliximab therapy for inflammatory bowel disease--seven years on

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1091308

Barriers to the prescription of systemic therapies for moderate-to-severe psoriasis--a multinational cross-sectional study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1091308

Inequities in access to biologic and synthetic DMARDs across 46 European countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1091308

Physicochemical characterization of Remsima

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1091308

A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1091308

A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1091308

Is extrapolation of the safety and efficacy data in one indication to another appropriate for biosimilars?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1091308

The challenge of indication extrapolation for infliximab biosimilars

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1091308

Efficacy of the new infliximab biosimilar CT-P13 induction therapy in Crohn's disease and ulcerative colitis - experiences from a single center.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1091308

Clinical Experience of the Use of CT-P13, a Biosimilar to Infliximab in Patients with Inflammatory Bowel Disease: A Case Series

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1091308

Infliximab, azathioprine, or combination therapy for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.1091308

10.1586/17474124.2015.1091308

21 January 2018

Identifiers

DOI

1 reference

13 May 2018

PubMed ID

26395534

1 reference

13 May 2018